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Abstract
Background: Certain studies suggest that using indocyanine green (ICG) could be comparable with using
radioisotopes (RI) in detecting sentinel lymph nodes (SLNs) in breast cancer. A number of these studies were
performed in Asia. The objective of our pilot study was to evaluate within a European population of breast cancer
patients the detection rate of SLNs using ICG and the HyperEye system and the concordance in SLNs detected
using this method and the standard method involving RI and a gamma probe.
Methods: Ten female patients with early-stage breast cancer (Czech Republic) indicated for partial mastectomy and
SLN biopsy were subjected to standard application of RI. Before surgery, ICG was administered periareolarly in the
amount of 1 ml of 0.5% solution. Sentinel lymph nodes were first detected perioperatively exclusively using ICG
fluorescence and the HyperEye device (Mizuho, Japan). Only after removal of all SLNs found in this way was the
standard hand-held gamma probe used to detect RI, and any potential additional SLNs not found with ICG were
then extirpated.
Results: In all 10 cases, at least one SLN was successfully detected using ICG. Nevertheless, in five patients, 1–4
additional SLNs were found using the gamma probe. Complete concordance in detecting SLNs therefore occurred
in only one half of the cases. Metastases in SLNs were found in a total of two cases. Had we used only ICG for
detection, one of these two cases would have been incorrectly evaluated as N0 (ICG false negativity).
Conclusions: The study did not confirm the hypothesis that the use of ICG with the HyperEye system can currently
be considered a method fully comparable with using RI and a gamma probe in a population of European patients.
Although the detection rate is high, a significantly lower number of SLNs were detected using ICG than
using RI (p = 0.03). Thus, there would be a higher probability for false negatives to occur in using SLN biopsy.
This is caused mainly by the limited permeability of tissues to fluorescent radiation and the difficulty
therefore of detecting nodes located deeper beneath the body’s surface.
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Background
Sentinel lymph node biopsy is today a standard surgical
procedure used in treating breast cancer and certain
other tumours. In practice, the location of a sentinel
lymph node (SLN) is determined using a tracer which is
usually radioactively marked albumin (radioisotope (RI))
or vital dye (usually patent blue). In breast cancer, the
combined method concurrently using RI and patent blue
has been regarded as the gold standard. Due to the con-
siderable risk of allergic reaction to patent blue [1], the
economic costs, and the cosmetically unfavourable blue
colouring of the skin, we have been noticing in recent
years a steering away from the combined method. In
non-complicated cases, some surgeons use only the
radioisotope. Meta-analyses have demonstrated that this
procedure is safe and does not increase the risk for false
negativity of the sentinel biopsy [2, 3]. Even the use of
the radioisotope by itself, however, requires that a nu-
clear medicine facility be available, and this is associated
with certain disadvantages relating to radioactivity.
Therefore, new methods and indicators are being sought
the use of which would be more suitable for clinical
practice.
Last year, we published our first experience using
superparamagnetic iron oxide particles detected using a
magneto-metric probe (SentiMag®) [4]. In accordance
with other previously published studies the results of
which were summarized in a meta-analysis [5], we did
not demonstrate inferiority and reached the conclusions
that this method is usable for detecting SLNs in breast
cancer and that it demonstrates a similar detection rate
and level of false negativity as when a radioisotope is
used. However, magnetic detection also is not ideal from
the practical perspective. A large volume of the detec-
tion substance must be applied (5 ml), plastic instru-
ments must be used in surgery and, above all, a certain
amount of the detection substance Sienna+® persists for
a long time at the application site. In patients after par-
tial mastectomy, this, according to our own not yet pub-
lished findings, conditions a brownish skin colouring
and creates a marked artefact in magnetic resonance
even a year after surgery.
Indocyanine green (ICG) could be another substance
potentially usable for detecting SLNs [3, 6]. Approved
for medicinal uses in 1956, it is commonly used today
for diagnosing liver functions, in ophthalmology, cardi-
ology and microcirculation diagnostics. Intravenous ap-
plication of ICG to human patients is safe, inasmuch as
the substance is quickly excreted from the body in the
bile. Upon visual inspection, it has a green colour. In
contrast to common dyes, however, it is a fluorophore
displaying fluorescence (i.e. the ability to emit a fluores-
cent signal in incident light). Upon being delivered into
the organism, ICG bonds to proteins and other
macromolecules. That changes the intensity of fluores-
cence and the emission spectrum to near infrared (NIR).
This radiation is invisible to the human eye but can be
detected using special devices with photodynamic cam-
eras [7]. Because the emitted radiation permeates
through tissues, in contrast to common dyes, it can also
visualize deeply located structures.
A large number of studies directed to use of ICG in
detecting SLNs in breast cancer have been published.
In a 1999 study by Japanese authors, ICG was used
only as a green dye without detecting NIR radiation
[8]. With the development of systems allowing for
perioperative detection of fluorescence, additional
studies used primarily this phenomenon for visualiz-
ing lymph vessels and nodes. The first studies from
2008 demonstrating the clinical usability of ICG for
visualizing the lymphatic system in the breast [9–16]
were followed by studies evaluating primarily the
combined use of the dye and ICG [17–21]. In work
to optimize the methodology, no clear advantage was
demonstrated from applying ICG conjugated with al-
bumin in comparison with application of just ICG
[22]. Certain newer studies, including one meta-
analysis, addressed the question as to whether detec-
tion using ICG is as successful as detection using a
radioisotope and whether ICG could be used on its
own as an adequate alternative [23–25]. The largest
study to date, published by Japanese authors in 2016,
tested the use of ICG while detecting fluorescence
using the HyperEye system by Mizuho (Japan). Those
authors reported a similar SLN detection rate (97.2%)
and sensitivity (95.7%) in comparison with the radio-
isotope. They deduced that detecting SLN in breast
cancer using ICG can be a comparable alternative to
using the radioisotope [26].
We decided to conduct a pilot study with the objective
of verifying the usability of ICG and the HyperEye sys-
tem for detecting SLNs in breast cancer patients in a
European population. The hypothesis was that ICG in
combination with the HyperEye system is usable in prac-
tice, that the detection rate using ICG reaches values in
excess of 90% and that in case of a combined use of ICG
and radioisotope, there would be concordance in SLNs
displayed with ICG and the radioisotope in an absolute
majority of patients. The study was performed at the
Masaryk Memorial Cancer Institute (Brno, Czech Re-
public) during the period February–March 2016 and was
approved by the Ethical Committee of the Masaryk Me-
morial Cancer Institute.
Methods
The study included 10 female patients with primary
breast cancer without clinical signs of axillary lymph
node metastases at the time of the diagnosis indicated
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for partial mastectomy and sentinel lymph node biopsy.
To be as close to usual clinical practice as possible,
no more stringent entry criteria were established.
Conditions for inclusion were provision of informed
consent and absence of previously known allergy to
indocyanine green or intravenous administration of
iodine preparations.
The patients underwent the usual preoperative proced-
ure including ultrasonographic localization of the position
of the primary tumour and lymphoscintigraphic examin-
ation as part of standard detection of the sentinel node
using a radioisotope and a hand-held gamma probe. On
surgery day, 99mTc nanocolloid (Nanocoll®) was adminis-
tered periareolarly in a dose of 100 MBq and the applica-
tion area was massaged for 20 min. In addition to the
usual procedure, ICG was applied after the patient was
put under total anaesthesia immediately before the start of
surgery. We applied ICG-PULSION 5 mg/ml intrader-
mally and subcutaneously in the periareolar area in the
amount of 1 ml of 0.5% solution. This was followed by
massaging the application location for at least 1 min. The
presence of ICG in the organism was perioperatively de-
tected using the HyperEye system by Mizuho, Japan
(Fig. 1), and visualized on a monitor placed on a rotating
arm beneath the ceiling of the operating room. The main
surgeon was always one of the two authors of this study.
Both are surgeons focusing exclusively on breast and skin
cancer surgery and with extensive experience in detecting
SLNs in a high-throughput work setting. The operating
surgeons had been trained in advance on using the Hyper-
Eye by an expert representative of the distributor.
In using the HyperEye system, the course of subcuta-
neous lymphatic vessels was visualized. The surgeon
made an incision at the place of the expected location of
the SLN. During continuous visualization using a photo-
dynamic camera, he endeavoured to identify and extir-
pate all nodes demonstrating fluorescence. Radioactivity
of the extirpated SLNs was recorded ex vivo using a
gamma probe. After this phase of the surgery was com-
pleted, the gamma probe was used for checking whether
marked substantial peaks of radioactivity persisted in the
axilla corresponding to other potential SLNs not identi-
fied using fluorescence. If such peaks were discovered,
the surgeon looked for and potentially extirpated these
additional SLNs. Using the HyperEye system, it was de-
termined ex vivo whether these SLNs manifested fluor-
escence. The following phase of the surgery was
according to usual practice. All extirpated SLNs were ex-
amined histologically, and the results were recorded.
The main evaluated parameters were success rate in de-
tecting the SLNs using ICG, match (concordance) in SLNs
detected by the individual methods, and with a special
focus on the match in detecting SLNs afflicted by metasta-
sis in the follow-up histopathological examination. The
numbers of SLNs found using only ICG and using the two
methods in combination were compared using Wilcoxon
signed-rank test (one-tailed) at the 5% level of significance.
Statistical analyses were performed using R version 3.2.4.
In addition, the practical aspects as to the usability of ICG
and the HyperEye system in clinical practice were assessed.
Results
The HyperEye system is usable in practice. Sterility is
achieved during surgery by means of a special one-use
PVC cover with a rigid plastic transparent camera cover.
Before the surgery, it is necessary to turn on the system in
advance and to calibrate it. This requires several minutes.
It is necessary somewhat to diminish the usual level of
lighting, at minimum by temporarily turning the operating
lights away from the field of surgery, better by turning off
the surrounding lighting or even darkening the room. This
is somewhat inconvenient during surgery and extends the
operating time. It was found to be impractical to carry out
the surgery itself with just the usual surgical team of two
surgeons. We brought in a third surgeon to control the
photodynamic camera. Figure 2 is a photograph from the
Fig. 1 The HyperEye system, Mizuho, Japan
Fig. 2 Perioperative visualization of fluorescent lymphatic collector
and a sentinel node on a monitor connected to HyperEye
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operating room demonstrating the visualization on a
screen of efferent lymphatic collector and SLN using the
HyperEye system.
All the main parameters are apparent from Table 1. In
all 10 cases, at least one sentinel node could be detected
using ICG itself. The median and mean number of
nodes detected and extirpated using ICG was equal to 1
and 1.3, respectively. All such SLNs removed were situ-
ated in the typical localization within the ipsilateral axilla
and ex vivo demonstrated, in addition to fluorescence,
also marked radioactivity. We assume, therefore, that we
would have found all these nodes also using RI and the
gamma probe. In five cases, no other SLNs were found
in subsequent control of the axilla using the gamma
probe. In the other five cases, however, between one and
four additional SLNs were subsequently found and extir-
pated using the gamma probe. All these additionally ex-
tirpated nodes demonstrated apparent fluorescence ex
vivo. Both the median and mean number of SLNs de-
tected per patient using both detection substances there-
fore reached 2.5. This number of nodes found using
both methods was significantly greater than the number
of nodes found using only ICG (p = 0.03). In one (of 10)
case, a macrometastasis was found only in one of the
SLNs found subsequently using RI and a gamma probe.
Meanwhile, the only SLN detected in that case using
ICG was negative. This was, therefore, a case of false
negativity of the tested method (ICG) in one case of two
where metastatic affliction in SLN occurred (ITC are not
considered metastatic afflictions).
Discussion
Our pilot study did not confirm the hypothesis that de-
tection of SLNs in breast cancer using ICG and the
HyperEye system appears to be a fully comparable alter-
native for detection to using a radioisotope and gamma
probe. Using just ICG, we successfully detected at least
one SLN in all 10 cases. In that sense, the detection rate
was 100%. In half of the cases, however, we subsequently
found additional SLNs. The number of SLNs found
using both methods was therefore significantly higher
than the number of nodes found using only ICG. In one
of the patients, a metastasis was found in one of the
additionally removed nodes while the only node detected
in that patient using ICG was negative. Complete match
in SLNs detected using both methods (concordance) was
therefore achieved in only 50% of cases. If the level of
false negativity of ICG was expressed numerically, it
would reach 50%. Considering the small number of
cases, however, we do not consider it appropriate to use
this number.
All nodes removed using ICG demonstrated ex vivo
high values for radioactivity and were localized in the
typical place within the ipsilateral axilla. In interpreting
the results, we therefore proceed from the assumption
that these nodes would have been found also using just
RI and gamma probe. There unfortunately is no real way
to prove this assumption, however, which is a slight
weakness of our study.
There can be several causes of what might be
termed the study’s “negative” outcome, which is to
say the non-confirmation of the hypothesis as to
comparability of ICG and radioisotope methods.
There exist various systems for perioperative detec-
tion of fluorescence from various manufacturers. The
FLARE system has been used for the longest time,
and it was relatively bulky and costly in its original
form [10]. This was followed by the development of
other lines with smaller dimensions [27]. As a prac-
tical matter, however, we could not examine these, as
was the case also regarding devices from other manu-
facturers. It is possible that the individual systems dif-
fer both in their practical aspects and by their
sensitivity in detecting fluorescence radiation. It can-
not be excluded, therefore, that we would have
reached different results using a different system. In
the largest of previously published positive studies
[26], however, the same system as in our case was
used (HyperEye). It is also probable that the intensity
of fluorescence emitted by lymph vessels and nodes
can be markedly influenced by the amount and con-
centration of ICG administered. The specific amount
administered differs in the individual studies. In our
study, we administered 1 ml of 0.5% solution—simi-
larly as did the authors of the aforementioned robust
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study—even though the distributor’s representative ini-
tially had recommended administration of an even smaller
amount (0.5 ml). The published meta-analysis indicates
that using a larger volume of the substance in a lower con-
centration could be more advantageous [24].
All sentinel nodes subsequently extirpated using a
gamma probe demonstrated ex vivo apparent fluores-
cence. The problem is therefore not that ICG would
be insufficiently transported into SLNs. Rather, it is
apparent that tissues’ permeability to NIR radiation is
limited such that the structures can only be visualized
to a certain depth not exceeding 1 cm [28]. Certain
facts support this notion. After intradermal periareo-
lar application, surface lymph vessels usually conver-
ging into a single collector passing over the upper
outer quadrant toward the axilla were well visualized
on the breast. Several centimetres before the axilla,
however, its trace on the skin disappeared, which we
explain by the collector’s sinking deeper into the sub-
cutaneous tissue. Fluorescent nodes were therefore
not apparent through the skin. It was necessary to
perform an incision into the expected location of the
SLN and to dissect it. The fluorescence emerging
from the efferent lymph vessel or SLN started to be
visible only deeper in the subcutaneous tissue or
under the axillary fascia. For a similar reason, in eight
cases out of 10, we found only one node using ICG.
If the other sentinel (fluorescent) nodes were not sit-
uated in the immediate vicinity of the first node re-
moved but lay deeper in the undissected tissue, they
were not visible. We intentionally avoided larger
“blind” dissection in the axilla as we would regard
that as excessive damage to the patients. Our assump-
tion as to the crucial influence of depth of the de-
tected structures on the success rate of visualization
is supported also by the conclusions of several other
studies. German authors have stated that body mass
index (BMI) higher than 40 is a limiting factor for
using ICG in breast cancer [29]. Although the highest
BMI in our patient set reached only 30.9, it is appar-
ent that deeper location of the SLNs in patients with
a stronger subcutaneous layer complicates their fluor-
escent detection. In malignant melanomas, where the ap-
proximate location of the sentinel node cannot be
empirically so well assumed, the node location could be
visualized percutaneously using fluorescence only in 17
cases of 80, and the authors of that study conclusively
state that radioisotope remains the gold standard for mel-
anoma [30]. There exists a possibility that a factor contrib-
uting to the positive results of studies performed in Asia is
the habitus of the local patients, which is somewhat differ-
ent from that of the European population. Sentinel lymph
nodes are located at a shallower depth, so the fluorescent
signal can be more apparent on the body surface.
The method cannot be considered ideal even with re-
spect to the practical use of ICG and the HyperEye sys-
tem. In order to preserve the surgeon’s comfort, an
additional worker is needed to control the camera.
Moreover, the darkening of the operating room during
visualization is somewhat inconvenient. Overall financial
costs must include those for depreciation of the device,
a special single-use cover with a plastic cover, and the
tracer (ICG).
Conclusions
Our pilot study confirmed a high detection rate of SLNs
in breast cancer patients using ICG and the HyperEye
system. It did not, however, confirm the assumption that
this method could be a fully comparable alternative in a
European population of patients to detecting SLNs using
radioisotope and gamma probe. This probably was
caused by the limited permeability of tissues to fluores-
cent radiation, which decidedly limits visualization of
more deeply situated lymph vessels and nodes.
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